KAZAN, Russian Federation, April 1 /CNW Telbec/ - Neuro-Biotech Corp.
(PinkSheets: MRES.pk - News) (OTCQB: MRES) and Auric Pharma Science
have accepted all terms and conditions and successfully completed all
due diligence requirements. Both companies have agreed to complete the
agreement on Tuesday April 5 at its new corporate head office in Kazan,
Mr. Boris Oleknovich, CEO and President of Neuro-Biotech Corp.
commented: "Merging these two incredible companies into one, can only
lead to great things, combining sales, research & development,
distribution channels and great scientific minds will make us a force
to be reckoned with. We would like to thank our shareholders for their
loyalty and to assure them that they will greatly benefit and profit
from our success."
"Mr. Oleknovich will remain President, I will assume the position of
CEO, together we will build a giant, We plan to open
manufacturing/production and distribution facilities in North America
in the near future." stated Mr. Norman Hathaway, President and CEO of
Auric Pharma Science.
For more information on Neuro-Biotech Corp or to contact a company
representative, please visit: www.neuro-biotechcorp.com.
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions, and
that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or obligation
to update or revise forward-looking information, whether as a result of
new information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
SOURCE Neuro-Biotech Corp.
For further information:
Mr Rustern Yusupov